Stop, Collaborate & Listen.

It might be a the opening lyric from a classic 90s pop/rap anthem, but it also could be the key for

smaller biotechs to stave off the funding demon and get the leg-up they need to position themselves amore investable company.

To explain more about the concept I spoke to Martino Picardo, CEO at Stevenage Bioscience

Catalyst (www.stevenagecatalyst.com), a potentially revolutionary system for up-and-coming

biotechs.

Q: Please briefly explain what Stevenage Bioscience Catalyst does...

MP: Stevenage Bioscience Catalyst (SBC) is part of a growing life sciences cluster in the South East of England, and is the UK’s first open innovation bioscience campus, pioneering a unique culture to drive early stage drug discovery and development. It is backed by £38m of funding from its founding partners – GlaxoSmithKline, the Wellcome Trust, the Department for Business, Innovation and Skills, the Technology Strategy Board and the East of England Development Agency. Scheduled to open in Q1 2012, buildings in Phase 1 of the development consist of an Incubator, an Accelerator and a Hub, covering 60,000 sq ft of laboratory, office and networking space. The independent facility is expected to house a range of companies, from virtual and start-up firms to those which are more established.

In short, our vision for Stevenage Bioscience Catalyst is:

“Access to world class resources, including superb high specification laboratories, funding and a

vibrant community for biotech growth and development”

To view the full interview, please visit www.biobusiness-conference.com